The University of Chicago Header Logo

Connection

Stephen Kent to Influenza Vaccines

This is a "connection" page, showing publications Stephen Kent has written about Influenza Vaccines.
Connection Strength

5.612
  1. Randomized trial of same- versus opposite-arm coadministration of inactivated influenza and SARS-CoV-2 mRNA vaccines. JCI Insight. 2025 01 09; 10(4).
    View in: PubMed
    Score: 0.774
  2. Poor protective potential of influenza nucleoprotein antibodies despite wide prevalence. Immunol Cell Biol. 2022 01; 100(1):49-60.
    View in: PubMed
    Score: 0.621
  3. Hemagglutinin Functionalized Liposomal Vaccines Enhance Germinal Center and Follicular Helper T Cell Immunity. Adv Healthc Mater. 2021 05; 10(10):e2002142.
    View in: PubMed
    Score: 0.593
  4. Fc functional antibody responses to adjuvanted versus unadjuvanted seasonal influenza vaccination in community-dwelling older adults. Vaccine. 2020 02 28; 38(10):2368-2377.
    View in: PubMed
    Score: 0.550
  5. Antibody-Dependent Cellular Cytotoxicity Responses to Seasonal Influenza Vaccination in Older Adults. J Infect Dis. 2017 12 27; 217(1):12-23.
    View in: PubMed
    Score: 0.475
  6. Antibody-dependent phagocytosis (ADP) responses following trivalent inactivated influenza vaccination of younger and older adults. Vaccine. 2017 11 07; 35(47):6451-6458.
    View in: PubMed
    Score: 0.468
  7. Antibody Responses with Fc-Mediated Functions after Vaccination of HIV-Infected Subjects with Trivalent Influenza Vaccine. J Virol. 2016 06 15; 90(12):5724-5734.
    View in: PubMed
    Score: 0.426
  8. IFN-gene signatures in B cells following influenza A and B virus infection and influenza vaccination. EMBO Mol Med. 2026 04; 18(4):1456-1477.
    View in: PubMed
    Score: 0.210
  9. Influenza-Specific T-Cell Responses to Vaccination Are Independent of Underlying Hematological Malignancy: Analysis of a Randomized Influenza Vaccination Trial. J Infect Dis. 2025 Dec 20; 232(6):1319-1329.
    View in: PubMed
    Score: 0.207
  10. Mucosal vaccination against SARS-CoV-2 using recombinant influenza viruses delivering self-assembling nanoparticles. Vaccine. 2025 02 06; 46:126668.
    View in: PubMed
    Score: 0.193
  11. Immunization with inactivated whole virus particle influenza virus vaccines improves the humoral response landscape in cynomolgus macaques. PLoS Pathog. 2022 10; 18(10):e1010891.
    View in: PubMed
    Score: 0.165
  12. Robust and prototypical immune responses toward influenza vaccines in the high-risk group of Indigenous Australians. Proc Natl Acad Sci U S A. 2021 10 12; 118(41).
    View in: PubMed
    Score: 0.154
  13. From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases. Acta Biomater. 2021 09 01; 131:16-40.
    View in: PubMed
    Score: 0.151
  14. Self-assembling influenza nanoparticle vaccines drive extended germinal center activity and memory B cell maturation. JCI Insight. 2020 05 21; 5(10).
    View in: PubMed
    Score: 0.140
  15. The protective potential of Fc-mediated antibody functions against influenza virus and other viral pathogens. Immunol Cell Biol. 2020 04; 98(4):253-263.
    View in: PubMed
    Score: 0.137
  16. A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer Interface. Cell. 2019 05 16; 177(5):1136-1152.e18.
    View in: PubMed
    Score: 0.131
  17. Subdominance and poor intrinsic immunogenicity limit humoral immunity targeting influenza HA stem. J Clin Invest. 2019 02 01; 129(2):850-862.
    View in: PubMed
    Score: 0.128
  18. Impact of serum versus anticoagulant-containing plasma on influenza virus neuraminidase-based serological assays. Vaccine. 2026 Jan 01; 69:127956.
    View in: PubMed
    Score: 0.051
  19. Immune cellular networks underlying recovery from influenza virus infection in acute hospitalized patients. Nat Commun. 2021 05 11; 12(1):2691.
    View in: PubMed
    Score: 0.038
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.